Essentials: Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson
Huberman Lab Podcast Recap
Published:
Duration: 39 min
Guests: Dr. Matthew Johnson
Summary
Psychedelics, including LSD and psilocybin, are being studied for their potential to treat mental disorders such as depression and addiction. Dr. Matthew Johnson discusses research findings, potential risks, and therapeutic mechanisms of these substances.
What Happened
Psychedelics are substances known to significantly alter one's perception of reality and self, with classic examples being LSD, psilocybin, DMT, and mescaline. These compounds act as agonists at the serotonin 2A receptor and can be classified into tryptamine-based and phenethylamine-based compounds.
Dr. Matthew Johnson mentions that psychedelics have been shown to aid in smoking cessation and depression treatment, even for individuals without pre-existing conditions. Psilocybin, typically administered in doses of 20-30 mg during studies, has demonstrated efficacy in promoting significant changes in self-representation, benefiting those with depression and addiction.
MDMA, another substance discussed, differs from traditional psychedelics as it affects both dopamine and serotonin levels, offering a distinct experience. It is considered potentially more suitable for trauma treatment due to its lower likelihood of causing adverse experiences known as 'bad trips.'
The episode also touches on the preparation process for psychedelic therapy, which includes psychiatric screening and building rapport with the guide. This preparation is crucial as psychedelics can cause dishabituation, making familiar stimuli appear novel, leading to therapeutic breakthroughs.
Psychedelics can induce neuroplasticity, which reshapes self-perception and identity. This property has led to interest in their potential for treating neurological injuries and cognitive improvements, particularly in retired athletes with head injuries.
Despite the promising applications, psychedelics can be destabilizing and should be used in safe environments. The risks include exacerbating severe psychiatric conditions like schizophrenia or mania, and about a third of high-dose psilocybin users report experiencing a bad trip, even in controlled settings.
Microdosing, another topic, lacks credible peer-reviewed studies showing benefits, with some research indicating no effects or slight impairments in tasks requiring time estimation. Anecdotal evidence suggests potential antidepressant effects, but more research is necessary to substantiate these claims.
Dr. Matthew Johnson emphasizes the need for ongoing research into the effects of psychedelics on the brain, including real-time imaging studies. This research could further elucidate the mechanisms behind their therapeutic effects and expand their potential applications.
Key Insights
- Classic psychedelics like LSD and psilocybin are serotonin 2A receptor agonists, and they can dissolve prediction models, altering perception and self-representation. This makes them promising in treating conditions like depression and addiction.
- MDMA, differing from serotonergic agents, increases both dopamine and serotonin, which is why it's considered potentially more effective for trauma treatment. It offers a unique therapeutic experience with a lower risk of inducing a 'bad trip'.
- Despite popular anecdotes, microdosing lacks scientific backing for benefits in cognitive or mood improvement. Some studies even suggest no effect or minor impairments in tasks requiring precise time estimation.
- Psychedelics promote neuroplasticity, which can aid in identity reshaping and self-perception. This property sparks interest in their potential to treat neurological injuries, especially in retired athletes with a history of head impacts.